Cargando…

Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma

BACKGROUND: The clinical consequences of pancreatic exocrine insufficiency and its treatment in advanced pancreatic ductal adenocarcinoma (PDAC) are poorly investigated. This retrospective study aims at investigating the pancreatic enzyme replacement therapy (PERT) use and its impact on survival and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trestini, Ilaria, Carbognin, Luisa, Peretti, Umberto, Sperduti, Isabella, Caldart, Alberto, Tregnago, Daniela, Avancini, Alice, Auriemma, Alessandra, Orsi, Giulia, Pilotto, Sara, Frulloni, Luca, Capurso, Gabriele, Bria, Emilio, Reni, Michele, Tortora, Giampaolo, Milella, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458827/ https://www.ncbi.nlm.nih.gov/pubmed/34568019 http://dx.doi.org/10.3389/fonc.2021.688889

Ejemplares similares

Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study
por: Trestini, Ilaria, et al.
Publicado: (2021)

Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome
por: Trestini, Ilaria, et al.
Publicado: (2020)

Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories
por: Sposito, Marco, et al.
Publicado: (2023)

Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report
por: Avancini, Alice, et al.
Publicado: (2020)

Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it
por: Trestini, I., et al.
Publicado: (2021)

Physical Activity for Oncological Patients in COVID-19 Era: No Time to Relax
por: Avancini, Alice, et al.
Publicado: (2020)

Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability
por: Avancini, Alice, et al.
Publicado: (2021)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial
por: Tabernero, Josep, et al.
Publicado: (2017)

Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned
por: Belluomini, Lorenzo, et al.
Publicado: (2021)

Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
por: Avancini, Alice, et al.
Publicado: (2019)

Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer
por: Agostini, Antonio, et al.
Publicado: (2023)

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
por: Bekaii-Saab, Tanios, et al.
Publicado: (2023)

Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
por: Merz, Valeria, et al.
Publicado: (2020)

Willingness, preferences, barriers, and facilitators of a multimodal supportive care intervention including exercise, nutritional and psychological approach in patients with cancer: a cross-sectional study
por: Avancini, Alice, et al.
Publicado: (2022)

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
por: Piro, Geny, et al.
Publicado: (2019)

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
por: Belluomini, Lorenzo, et al.
Publicado: (2020)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022)

Factors Influencing Physical Activity in Cancer Patients During Oncological Treatments: A Qualitative Study
por: Avancini, Alice, et al.
Publicado: (2020)

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
por: Tempero, Margaret A., et al.
Publicado: (2023)

Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma
por: Trestini, Ilaria, et al.
Publicado: (2021)

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
por: Carbognin, Luisa, et al.
Publicado: (2015)

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma
por: Reni, Michele, et al.
Publicado: (2016)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo
por: Saito, Nobuhiro, et al.
Publicado: (2018)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
por: Tsujimoto, Akiko, et al.
Publicado: (2019)

Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
por: Winer, Arthur, et al.
Publicado: (2021)

Fibroblast inhibition by tocilizumab enabled gemcitabine/nab‐paclitaxel rechallenge for pancreatic cancer
por: Mitsunaga, Shuichi, et al.
Publicado: (2023)

Exercise Levels and Preferences in Cancer Patients: A Cross-Sectional Study
por: Avancini, Alice, et al.
Publicado: (2020)

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
por: Williet, Nicolas, et al.
Publicado: (2021)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Pancreatic steatosis and metabolic pancreatic disease: a new entity?
por: Caldart, Federico, et al.
Publicado: (2023)

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2019)

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020)

Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
por: Ceccon, Garry, et al.
Publicado: (2020)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f1flhucr58qg1mtmg6h08dhnen